Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Odin Kuiper

Obstetrics & Gynecology Avon, CT Medical Doctor

NPI 1801987201 CMS profile 1268378

20 West Avon Rd, Avon, CT 06001

Open in the dashboard

General payments

$1,239

32 records reported · program years 2019–2025

Research payments

$50,658

Paid to them · 43 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Odin Kuiper of Avon, CT is reported in the CMS Open Payments database as having received $1,239 across 32 general payments and $50,658 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39 1
2024 General $175 9
2024 Research $8,336 8
2023 General $57 4
2023 Research $5,356 10
2022 General $492 6
2022 Research $6,466 7
2021 General $38 2
2021 Research $5,375 3
2020 General $337 7
2020 Research $21,526 11
2019 General $101 3
2019 Research $3,600 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Odin Kuiper
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Odin Kuiper were reported at $39. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Odin Kuiper Obstetrics & Gynecology median Middle half National median
2019 $101 $172 $62–$391 $163
2020 $337 $94 $36–$222 $114
2021 $38 $136 $42–$369 $132
2022 $492 $160 $50–$433 $149
2023 $57 $169 $56–$423 $160
2024 $175 $152 $50–$371 $164
2025 $39 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Covidien LP $397 7 payments
  2. Hologic, LLC $263 4 payments
  3. Medtronic, Inc. $203 12 payments
  4. Acessa Health Inc. $197 1 payment
  5. Coloplast Corp $39 1 payment
  6. Channel Medsystems, Inc. $36 1 payment
  7. Applied Medical Resources Corporation $31 1 payment
  8. Avion Pharmaceuticals $27 2 payments
  9. Evofem Biosciences, Inc. $16 1 payment
  10. Olympus America Inc. $16 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $645 24 payments
  2. Travel and Lodging $594 8 payments
Products named General payments · program years 2019–2025
  1. ACESSA PROVU SYSTEM $460 5 payments
  2. DEFINITY CERVICAL DILATOR, 5MM $137 1 payment
  3. MYOSURE TISSUE REMOVAL DEVICE $43 1 payment
  4. OMNI HYSTEROSCOPE $43 1 payment
  5. Altis $39 1 payment
  6. GelPOINT V-Path $31 1 payment
  7. Balcoltra $27 2 payments
  8. Phexxi $16 1 payment
  9. PREMARIN $14 1 payment
  10. COLOGUARD $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $25,533 28 payments
  2. Covidien LP $25,126 15 payments

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

172

Median for Obstetrics & Gynecology: 65

Drug cost

$21,781

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

72.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imvexxy Estradiol Brand 20 $10,850
Estradiol (Twice Weekly) Estradiol Brand 32 $3,608
Estradiol (Once Weekly) Estradiol Brand 19 $2,302
Estradiol Generic 48 $1,967
Yuvafem Estradiol Brand 18 $1,617
Valacyclovir Valacyclovir Hcl Brand 12 $964
Progesterone Progesterone, Micronized Brand 23 $473

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$5,430

Medicare's payments for the services billed

Medicare patients

48

Average age 71

Services billed

95

48 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 42%
Arthritis 42%
Diabetes 27%
Osteoporosis 25%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record